Aquaporin-4 prevents exaggerated astrocytosis and structural damage in retinal inflammation.
AQP4
Astrocytosis
EAE
GFAP
OCT
OCT angiography
Retina
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
06
12
2021
accepted:
26
04
2022
revised:
08
04
2022
pubmed:
11
5
2022
medline:
9
6
2022
entrez:
10
5
2022
Statut:
ppublish
Résumé
Aquaporin-4 (AQP4) is the molecular target of the immune response in neuromyelitis optica (NMO) that leads to severe structural damage in the central nervous system (CNS) and in the retina. Conversely, AQP4 might be upregulated in astrocytes as a compensatory event in multiple sclerosis. Thus, the functional relevance of AQP4 in neuroinflammation needs to be defined. Here, we tested the role of AQP4 in the retina in MOG(35-55)-induced experimental autoimmune encephalomyelitis (EAE) using optical coherence tomography (OCT), OCT angiography, immunohistology, flow cytometry, and gene expression analysis in wild-type and Aqp4
Identifiants
pubmed: 35536323
doi: 10.1007/s00109-022-02202-6
pii: 10.1007/s00109-022-02202-6
pmc: PMC9166880
doi:
Substances chimiques
Albumins
0
Aquaporin 4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
933-946Informations de copyright
© 2022. The Author(s).
Références
Ann Neurol. 2015 Nov;78(5):801-13
pubmed: 26190464
Brain. 2016 Nov 1;139(11):2855-2863
pubmed: 27581073
Neurology. 2015 Feb 17;84(7):720-8
pubmed: 25609766
J Neuroinflammation. 2013 Oct 04;10:120
pubmed: 24090415
Neurology. 2021 Jul 13;97(2):68-79
pubmed: 33910937
Acta Neuropathol Commun. 2019 Jul 31;7(1):125
pubmed: 31366377
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6519-23
pubmed: 20574022
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 15;8(6):
pubmed: 34526385
Eur J Immunol. 2017 Mar;47(3):458-469
pubmed: 28058717
J Cell Biol. 1983 Jul;97(1):253-7
pubmed: 6345555
Biochim Biophys Acta. 2006 Aug;1758(8):1085-93
pubmed: 16564496
Exp Eye Res. 2010 Jan;90(1):17-25
pubmed: 19748503
Sci Transl Med. 2020 Mar 25;12(536):
pubmed: 32213628
Mol Neurobiol. 2019 Dec;56(12):8589-8602
pubmed: 31280447
Neurosurg Focus. 2007 May 15;22(5):E3
pubmed: 17613234
Nat Med. 2007 Apr;13(4):423-31
pubmed: 17384649
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
Acta Neuropathol. 2021 Nov;142(5):899-915
pubmed: 34487221
Exp Eye Res. 2016 Apr;145:158-163
pubmed: 26607807
Brain. 2007 May;130(Pt 5):1194-205
pubmed: 17282996
Acta Neuropathol. 2007 Feb;113(2):187-94
pubmed: 17143632
Nat Rev Neurol. 2015 Aug;11(8):457-70
pubmed: 26195256
Invest Ophthalmol Vis Sci. 2012 May 17;53(6):2921-7
pubmed: 22447858
BMC Neurosci. 2009 Aug 06;10:94
pubmed: 19660138
Lancet Neurol. 2018 Nov;17(11):1016-1024
pubmed: 30353860
Mult Scler J Exp Transl Clin. 2019 Sep 05;5(3):2055217319871582
pubmed: 31523449
Eur J Neurosci. 2018 Jun;47(12):1429-1443
pubmed: 29790615
Mult Scler. 2016 Jun;22(7):893-900
pubmed: 26362905
Acta Neuropathol Commun. 2019 Jul 17;7(1):116
pubmed: 31315675
Nat Med. 2000 Feb;6(2):159-63
pubmed: 10655103
Nat Rev Neurosci. 2014 Jul;15(7):431-42
pubmed: 24894585
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
Nat Rev Neurosci. 2018 May;19(5):283-301
pubmed: 29618808
Brain. 2016 Nov 1;139(11):2816-2819
pubmed: 29106485
Ophthalmology. 2014 Jan;121(1):142-149
pubmed: 24139122
Brain. 1990 Oct;113 ( Pt 5):1477-89
pubmed: 2245307
Behav Brain Res. 2018 Oct 15;352:172-182
pubmed: 28760697
J Clin Invest. 1997 Sep 1;100(5):957-62
pubmed: 9276712
J Autoimmun. 2014 Nov;54:93-9
pubmed: 25129503
JCI Insight. 2021 Jun 8;6(11):
pubmed: 34100385
J Autoimmun. 2015 Jan;56:34-44
pubmed: 25282335